Daniel F. Hogan

International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study

Philip R. Fox, Bruce W. Keene, Kenneth Lamb et al. · Journal of Veterinary Internal Medicine · 2018 · 152 citations · Full text

Medicine, Cardiology, Veterinary Epidemiology +14

Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT)

Daniel F. Hogan, Philip R. Fox, Kristin A. Jacob et al. · Journal of Veterinary Cardiology · 2015 · 134 citations

Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +9

Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats

Philip R. Fox, Mark A. Oyama, Caryn Reynolds et al. · Journal of Veterinary Cardiology · 2009 · 113 citations

Medicine, Cardiology, Veterinary Internal Medicine +14

Multicenter Evaluation of Plasma N-Terminal Probrain Natriuretic Peptide (NT-pro BNP) as a Biochemical Screening Test for Asymptomatic (occult) Cardiomyopathy in Cats

Philip R. Fox, John E. Rush, Caryn Reynolds et al. · Journal of Veterinary Internal Medicine · 2011 · 100 citations · Full text

Medicine, Cardiology, Veterinary Internal Medicine +14

Antiplatelet effects and pharmacodynamics of clopidogrel in cats

Daniel F. Hogan, Dina A. Andrews, Henry W. Green et al. · Journal of the American Veterinary Medical Association · 2004 · 92 citations · Full text

Medicine, Pharmacology, Veterinary Pharmacology +17